關於 cookie 的說明

本網站使用瀏覽器紀錄 (Cookies) 來提供您最好的使用體驗,我們使用的 Cookie 也包括了第三方 Cookie。相關資訊請訪問我們的隱私權與 Cookie 政策。如果您選擇繼續瀏覽或關閉這個提示,便表示您已接受我們的網站使用條款。

搜尋結果Search Result

符合「Cosmetics & Personal Care」新聞搜尋結果, 共 273 篇 ,以下為 1 - 24 篇 訂閱此列表,掌握最新動態
Kotex Global Study Finds Nearly 60% of Women Feel Progress is Lacking and Launches #ProgressFeelsLike Movement to Ignite Action on International Women's Day

Kotex, champion of women's progress for 100+ years, launches provocative next phase of its "She Can Initiative" to generate awareness around study and drive systemic change DALLAS, Feb. 27, 2024 /PRNewswire/ -- Kimberly-Clark's (NYSE:KMB) Kotex, creator of the period care category, is marking International Women's Day (March 8) by releasing eye-opening data from a study around how women worldwide feel about progress. Kotex uncovered that nearly 60% of women believe that the speed of women's progress is either stagnant or moving slowly. Half of the women polled indicated that the world is a more uncomfortable place for them than ever before. Furthermore, the study showed that these sentiments are relatively stronger among the younger generation. With this data top of mind, Kotex is launching its #ProgressFeelsLike effort to speak to this serious threat and encourage women around the world to have a voice and share their view of what progress is like in their daily lives and in the world around them. "In a long history of advancement of women's rights and equality, today we are reminded that progress isn't a given," said Alison Lewis, chief growth officer at Kimberly-Clark. "Now is a crucial time for women everywhere to use their voices to inspire change, and we are pleased to offer a platform to share what #ProgressFeelsLike from their viewpoint. On International Women's Day and every day, #ProgressFeelsLike unites us and empowers us in our pursuit of progress across every culture and every country in the world. Because period or not, She Can." To help show the world what #ProgressFeelsLike, Kotex is debuting a provocative film produced by an all-female Kotex team in partnership with Capital A Creative and Rakish, led by renowned director, Jaci Judelson. The powerful #ProgressFeelsLike film speaks to the data unearthed in Kotex's study. It depicts the reality around the globe that women face bias related to inequality, their periods and other restrictions, which continue to challenge or hinder progress. Kotex is encouraging women worldwide to participate in the movement by using #ProgressFeelsLike in social media posts. The period care brand is also organizing on-the-ground activations to ignite conversation and inspire change for women within their communities. Examples include: In Turkey, Kotex is increasing its commitment to women's progress to ensure a more comfortable world where women can express themselves freely and break menstrual taboos. For every tweet using #ProgressFeelsLike in Turkey, the Kotex team will make a matching product donation to non-profit women's organizations. In Brazil, Kotex is launching a digital art festival to visually depict what #ProgressFeelsLike and to celebrate women's achievements, question the stigmas around menstruation, and show that women haven't come this far to stop here. In the US, U by Kotex will donate two period products to Alliance for Period Supplies from the purchase of any U by Kotex product purchased at Walmart during March 2024. U by Kotex will also donate two additional period products to APS for each repost of its social media post for National Women's Day on March 8, 2024, to drive awareness of period poverty, an issue that impacts one in three low-income women in the US. In Vietnam, Kotex is launching a music video that calls for consumers to submit entries that speak to what #ProgressFeelsLike when it comes to chasing their dreams. The top three winners will receive a $5,000 scholarship to make their ideas a reality. As part of the #ProgressFeelsLike movement, Kotex is leading by example and has formed a new partnership with She's the First, a non-profit organization that fights for a world where every girl can choose her own future. As a part of the partnership with She's the First, Kotex is standing behind its pledge to progress and donating funds to help support the organization's mission to make sure girls everywhere are respected, educated and heard. The #ProgressFeelsLike movement and new alliance with She's the First is an extension of Kotex's She Can Initiative and existing work with Plan International and WASH United. The three partnerships align with Kotex's ongoing mission to champion women's progress by fighting period stigmas and the barriers they cause, by promoting access to education in schools and communities and by helping to open doors so women gain equal opportunity. Click here to view and download the #ProgressFeelsLike infographic. Click here to watch the film. Click here for more information about the Kotex #ProgressFeelsLike movement and She Can Initiative. For press inquiries contact Abby Hagstrom, abby@thescratchcollective.com. *= Kotex's Global Consumer Insights Study, September 2023 Total N = 3500. Full study available by request. About KotexOur Kotex, U by Kotex, and Intimus brands aim to ensure a period never gets in the way of any woman's progress. Kimberly-Clark created the period care category with the launch of the Kotex brand 100 years ago, and today, its products are trusted by millions of women in more than 100 countries to provide outstanding protection and inspire confidence that period or not, she can. About Kimberly-ClarkKimberly-Clark (NYSE: KMB) and its trusted brands are an indispensable part of life for people in more than 175 countries and territories. Fueled by ingenuity, creativity, and an understanding of people's most essential needs, we create products that help individuals experience more of what's important to them.  Our portfolio of brands, including Huggies, Kleenex, Scott, Kotex, Cottonelle, Poise, Depend, Andrex, Pull-Ups, GoodNites, Intimus, Plenitud, Sweety, Softex, Viva and WypAll, hold No. 1 or No. 2 share positions in approximately 70 countries.  We use sustainable practices that support a healthy planet, build strong communities, and ensure our business thrives for decades to come. We are proud to be recognized as one of the World's Most Ethical Companies(R) by Ethisphere for the fifth year in a row. To keep up with the latest news and to learn more about the company's 150-year history of innovation, visit kimberly-clark.com. About She's the FirstShe's the First is a global girls' rights organization that fights for a world where every girl can choose her own future. They team up with grassroots leaders to make sure girls everywhere are educated, respected, and heard. Over the past 13 years, they've created transformational outcomes for 563,741 girls by working alongside 685 community organizations in 42 countries. To fulfill their mission, they teach a girl how to speak up for herself in her home, school, and community, while they teach the mentors in her life practical ways to support her agency. As a result, these girls become the first women in their families to achieve amazing milestones—and they are never the last. Their diverse team is based across the U.S., Kenya and Guatemala. They've built a strong reputation as an anti-oppressive and girl-centered organization. Their leadership in the girls' empowerment space is recognized by former First Lady Michelle Obama, the United Nations, the Clinton Global Initiative, Women Deliver and the DVF Awards. [KMB-C]  

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 53 加入收藏 :
OMANI HIGH PERFUMERY HOUSE AMOUAGE OPENS ITS FIRST POP UP BOUTIQUE IN CHINA

SHANGHAI, Feb. 27, 2024 /PRNewswire/ -- Amouage, the High Perfumery House from the Sultanate of Oman, is delighted to announce the grand opening of its first pop-up boutique in China, its first ever foothold in mainland China. AMOUAGE's POP UP BOUTIQUE IN CHINA Located in the historic Zhang Yuan (also known as Zhang s Garden) community of Shanghai, the boutique is designed to offer a unique, immersive experience for consumers. Amouage is an addition to an elevated and sophisticated landscape amongst many cultural landmarks and will welcome customers from December 2, 2023, until May 2024. The pop-up construction features the elements of the brutalist style developed by Renaud Salmon, Chief Creative Officer, sees burnt cork, travertine and sandstone elements with radiating luminosity to reflect the heritage and sensations of the Sultanate of Oman, highlighting the perfume creations introduced in the past years. In 2020, Amouage partnered with S'Young International to enter and gradually expand in the Chinese market. In August 2021, Amouage successfully opened a flagship online store on Tmall Global, China's largest cross-border eCommerce platform. Aligning with the brand 40(th) anniversary in 2023, the opening of Amouage s first physical pop-up boutique in China will not only commemorate the milestone but also establish a solid groundwork for the brand's expansion into the booming Chinese perfume market. ABOUT AMOUAGE Amouage is an independent Omani High Perfumery House renowned for creating some of the most finely crafted perfumes in the world. Founded in the Sultanate of Oman in 1983 to be 'The Gift of Kings', the House has redefined the Arabian art of perfumery and garnered a global reputation for bringing innovative modernity and true artistry to all its creations. Masterfully paying tribute to its heritage, Amouage is a unique fusion of East meets West that defines avant-garde opulence. Today, it expresses the contemporary majesty of Oman, a historic trading centre for frankincense around the globe, with arresting and alluring collections that speak to a sophisticated, confident, and well-travelled discerning clientele who seek something compellingly precious, extraordinary and personal, every day. 

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 58 加入收藏 :
APAX Medical Introduces Cutting-Edge ADVATx Laser For Skin Rejuvenation

SINGAPORE, Feb. 26, 2024 /PRNewswire/ -- APAX Medical & Aesthetics Clinic is proud to announce the introduction of the ADVATx laser treatment by Advalight in their offerings - a revolutionary laser system that targets both active acne and acne scars simultaneously. This innovative solution utilises two laser wavelengths, offering a unique and comprehensive approach to dermatological care. Set to launch on 1 March 2024, the Advalight treatment is a game-changer for individuals seeking advanced and effective acne and acne scar removal treatment in Singapore. The ADVATx laser treatment sets itself apart by addressing the dual challenge of active acne and acne scars in a single procedure. By targeting inflammation, sebaceous glands, and acne scars concurrently, this cutting-edge therapy provides a more holistic solution compared to traditional approaches. Not only does it excel in acne management, post acne redness, pigmentation and scarring, but it also extends its efficacy to treat conditions like rosacea, melasma, red or hypertrophic scars, and broken capillaries. Acknowledging the challenges associated with acne relapse, APAX Medical & Aesthetics Clinic emphasises the importance of maintenance therapy with topical retinoids. Early intervention is crucial to preventing potential scarring and enhancing the overall quality of life for patients. The ADVATx laser treatment aligns with APAX Medical's commitment to comprehensive skincare, addressing challenges head-on to deliver optimal results. Studies have found that acne scarring affects up to 95% of patients with acne, and is severe in 30% of cases, leading to long-term effects like poor self-esteem, anxiety, depression, and social impairment, emphasising the importance of treating active acne and acne scars concurrently to reduce disease burden and potential scarring. Recognising this need, ADVATx laser treatment is APAX Medical's latest addition to an impressive portfolio of services. APAX Medical's commitment to advancing skincare solutions, including treatment for cystic acne, acne scars, hormonal acne, back acne and more, is reflected in its history of delivering exceptional results and building a diverse client portfolio. APAX Medical's unveiling of the ADVATx laser treatment marks a significant milestone in the management of acne and acne scars. With a rich history of excellence, APAX Medical & Aesthetics Clinic addresses acne comprehensively and aims to position itself as a leader in providing cutting-edge solutions for skincare. For further information or inquiries, please visit https://apaxmedical.com/.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 202 加入收藏 :
PRADA FALL/WINTER 2024 WOMENSWEAR SHOW

Beauty looks created by Lynsey Alexander, Global Makeup Artist of Prada Beauty MILAN, Feb. 23, 2024 /PRNewswire/ -- The Prada Fall/Winter 2024 Womenswear fashion show was held on February 22, 2024 inside the Deposito at Fondazione Prada, Milan. To view the Multimedia News Release, please click: https://www.multivu.com/players/uk/9252851-prada-fall-winter-2024-womenswear-show/ **FACE** Lynsey Alexander starts by preparing the skin with Prada Skincare, employing Prada Augmented Skin The Essence as the first step. This transformative 2-in-1 toner and micro-peel essence optimizes and renews skin texture while gently exfoliating to prepare skin for the steps that follow. Next, Lynsey applies Prada Augmented Skin The Serum, a cream to water serum to even and refine the skin tone, before applying Prada Augmented Skin The Cream, ensuring its complete absorption before application of the base. Lynsey then applies Prada Reveal Foundation to achieve a naturally diffused, soft-matte finish. As the final step and to add dimension, Lynsey gently pads The Serum across the cheekbones to create a glossy veil, then dabs a minimal amount of Prada Monochrome Lipcolor in nude hues, mostly employing the B13 Marron for the runway, and the Prada Balm for a diffused glow on the cheeks. **BROWS** To frame the eyes with softness, Lynsey re-invents the use of the foundation by delicately brushing the Prada Reveal Foundation onto brows, sculpting a gentle and minimal arc and centering focus to the eyes. Lynsey finishes by lightening the brows with nude shades of the Prada Dimensions Eyeshadow palettes. Depending on skin tone, Lynsey adapts the use of palettes 05 Pure, 01 Portrait, and 03 Pulse to achieve a delicate yet intriguing look. **LIPS** To prepare the lips, Lynsey applies Prada Balm as a lip primer to moisturize and enhance the natural look of the lips. Lynsey then dabs on the NEW Prada Monochrome Lipcolor Nude lipsticks, highlighting the shades P159 Nudo and B13 Marron to curate a hydrating, soft-matte finish that flatters all skin tones. The result is a uniform, diffused lip that perfectly complements a modern nude face. Product List: Face: Prada Augmented Skin The Essence Prada Augmented Skin The Serum Prada Augmented Skin The Cream Prada Reveal Skin Optimizing Foundation Brows: Prada Reveal Foundation Dimensions Eyeshadow 05 Pure, 01 Portrait, 03 Pulse Prada Tools 06 Eye Shaping Brush Prada Tools 07 Eye Defining Brush Lips: Prada Balm Prada Monochrome Lipstick in Shades P159 Nudo and B13 Marron Images available at the following link: https://we.tl/t-x1XhNF7K7D Photographer Credit: Marco Lessi Prada Beauty at Prada FW24 Womenswear Show    

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 109 加入收藏 :
Pierre Fabre Laboratories, committed to combating rare pediatric diseases via innovative therapies

70% of rare genetic diseases start in childhood[1,2] CASTRES, France, Feb. 23, 2024 /PRNewswire/ -- Rare Disease Day® will be held on February 29, an opportunity for Pierre Fabre Laboratories to reiterate our desire to provide innovative prescription drugs to children, as young patients require appropriate treatments. Already recognized for our work in oncology and dermatology, for several years Pierre Fabre Laboratories has been involved in rare diseases, which affect more than 200 million children worldwide[1,2]. In this area more than any other, partnerships are essential for driving research forward and discovering new treatments. Working with the EspeRare Foundation to treat XLHED: Pierre Fabre Laboratories is committed, alongside the EspeRare Foundation, to developing an innovative in utero therapy for the most common form of ectodermal dysplasia, XLHED, a rare genetic disease that acts on structures including the sweat and respiratory glands, skin, hair and teeth, and affects 500 infants each year worldwide. "As the mother of a little boy affected by Ectodermal Dysplasia, a rare and unknown genetic disease that permanently affects the sweat glands, hair, teeth and nails, I am deeply committed to the Association Française des Dysplasies Ectodermiques (AFDE). The association has been existing for more than 20 years and offers essential support to affected families who sometimes suffer from the difficult view of others and from medical wandering. We support families and make their daily lives easier. We organise national days and trips to encourage meetings and exchanges. We are also involved in research projects such as the EDELIFE clinical trial on the prenatal treatment of the most common form of the disease, XLHED, conducted by Pierre Fabre laboratories and the EspeRare Foundation. This opportunity to take part in medical research is a real opportunity for children and their families giving us new hope." – Muriel Dubreuilh, President of Association Française des Dysplasies Ectodermiques (AFDE) EDELIFE, a clinical study involving pregnant women carrying a fetus with the disease gene, was launched in late 2021. For more information: https://edelifeclinicaltrial.com/en-us/, Edelife clinical trial - Ectodermal dysplasia, Article from New England Journal of Medicine. Partnering with Atara Biotherapeutics to treat a very rare lymphoproliferative disease (EBV+ PTLD): In oncology, Pierre Fabre Laboratories and the Californian biotech Atara Biotherapeutics have been working in partnership since 2021 to treat relapsed or refractory Epstein-Barr virus positive post-transplant lymphoproliferative disease (EBV+ PTLD) in patients aged two years or over who have undergone at least one previous treatment.  This promising treatment was approved by the European Medicines Agency (EMA) in December 2022, and is currently marketed in Germany and Austria. In France, it has been available for patients as part of an early access program 2 (AP2) since July 2023.  In France in particular, in the context of a serious, rare and incapacitating disease with a bleak prognosis, tabelecleucel, an innovative orphan drug, could meet a non-covered medical need for around five children a year. "Our companies' complementary capabilities will expand access to the first allogeneic immunotherapy to use T cells from a healthy donor for patients all over the world who suffer from this rare form of cancer." –  Pascal Touchon, CEO of Atara Biotherapeutics, Inc. Last December in Paris, this treatment won the 2023 Prix Galien France award in the Innovative Therapy Drugs category. This award is emblematic of scientific rigor, excellence and innovation, recognizing remarkable recent innovations in health care and publicly available. This therapeutic innovation will be put forward for the 2024 International Prix Galien, which will be awarded in Rome this June. Working with Bordeaux University Hospital to treat infantile hemangioma: Infantile hemangioma, occurring in 4.5% of infants under one year of age, is the most frequently observed benign tumor[3-5]. In 90% of cases, these tumors are not serious, but in some cases they are harmful. In 2007, the Bordeaux University Hospital discovered by chance that a molecule frequently used in cardiology was effective at treating this pediatric skin disease. After fruitful cooperation between the University Hospital and Pierre Fabre, this chance discovery became a concrete reality in 2014, with the global commercialization of the first prescription drug to treat severe infantile hemangioma. Realizing that families were seriously lacking information, Pierre Fabre laboratories set up an extensive French website aimed at parents of children presenting with infantile hemangioma, to provide them with all the information they needed and help them determine the best course of action from birth onwards. Rapid detection of infantile hemangioma enables better management and limits the risk of sequelae. For more information: https://www.hemangiome.com. For health care professionals, the provision of the Infantile Hemangioma Referral Score (IHReS), developed with the support of Pierre Fabre Laboratories, expedites the patient care pathway via early identification of patients to be referred to a specialist center (https://www.ihscoring.com). "The general wait-and-see attitude that has prevailed around infantile hemangiomas must now be replaced with a more active approach. The IHReS score helps pediatricians and general practitioners identify hemangiomas with a risk of complications so the children can immediately be referred to a specialist center able to start treatment." – Dr. Christine Labrèze, dermatologist at Bordeaux University Hospital Working with Association Ichtyose France to improve management of ichthyosis Dermatology is the branch of medicine that has the largest number of rare disorders worldwide. 500 have been reported, all with very different forms. Ichthyosis is a rare disease that mainly affects the skin, significantly altering the integrity of the skin's barrier function. It is characterized by desquamation ranging from mild yet unpleasant dryness to a more serious disorder that is difficult to live with day after day.  To understand and help improve patient quality of life, Pierre Fabre Laboratories, in collaboration with patient associations, is collecting data as part of the Visible Diseases of the Skin program (in particular, the ALL study an epidemiological survey conducted over 50,000 people in 20 countries). In 2023, a specific study was conducted with four European ichthyosis organizations. Responses were received from 362 patients, enabling previously non-existent information to be collected about their experiences. The results were presented by each organization during the annual event with the patients' families and experts. Ichthyosis affects around 1% of all people[6]. Its visibility on the hands and face makes it very disabling from a very young age: 67% of patients in the study reported feeling excluded[6]. "Thank you Pierre Fabre […] for […] setting up this study, […] because, as sufferers of a rare disease, it's important for us to be heard and acknowledged, and these figures are going to help us with that. Our long-term relationship with Pierre Fabre is a good illustration of the close links forged with patients and patient associations, year after year!" – Anne Audouze, President of Association Ichtyose France, a non-profit organization dedicated to ichthyosis About rare diseasesThe European Union defines a rare disease as a rare condition affecting fewer than one in 2,000 people (in other words, a few dozen or a few hundred patients for a given disease). There are thought to be between 5,000 and 8,000 rare diseases7 (neuromuscular diseases, metabolic disorders, infectious and auto-immune diseases, rare cancers, etc.), affecting 3 million people in France, 30 million in Europe and over 300 million patients worldwide[8]. Although they concern relatively few individual patients, they affect a significant proportion of the population, and emerge as a real global public health issue.   About Pierre Fabre Laboratories For more information, please visit www.pierre-fabre.com, @PierreFabre. 1. https://www.rarediseaseday.org.2. European Journal of Human Genetics (2020) 28:165–173.3. Léauté-Labreze et al – Infantile Haemangioma –Lancet 2017 Jul 1;390 (10089): 85-94.4. Munden et al – Incidence and demographics of IH – BJD 2014, 170; 907-913.5. Volc-Platzer et al. – Poster ESPD 2014.6. El Hachem et al., Ichthyosis: multinational European study on patient characteristics and body sites involved with impact on quality of life, British Journal of Dermatology (sous presse).7. https://www.ema.europa.eu/en/human-regulatory/overview/orphan-designation-overview.8. https://www.inserm.fr/c-est-quoi/300-millions-patients-quand-meme-c-est-quoi-maladies-rares/. Press contact :Laurence Marchallaurence.marchal@pierre-fabre.com

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 569 加入收藏 :
Innovative C-Beauty: Florasis Launches Nomadic Glam at @cosme Tokyo

TOKYO, Feb. 23, 2024 /PRNewswire/ -- Florasis, a leading innovator in the C-beauty industry, announces the esteemed launch of the Nomadic Glam Collection, available from February 21st to March 12th at the @cosme store in Tokyo. This pop-up event is an homage to the rich cultural fabric, beauty, and ingenuity, inspired by the nomadic traditions of China's ethnic Mongolian culture and the captivating landscapes of Northern China. Florasis, a leading innovator in the C-beauty industry, announces the esteemed launch of the Nomadic Glam Collection, available from February 21st to March 12th at the @cosme store in Tokyo. The Nomadic Glam Collection encapsulates the essence of nature and the spirit of adventure. The lineup, featuring the "Into the Wild" eyeshadow palette, ultra-smooth satin liquid lipsticks, Flawless Jade foundation, among others, is designed to bring the vitality of the prairies into everyday beauty routines. Each purchase of the Flawless Jade foundation is paired with a complimentary refill, underscoring Florasis' commitment to sustainability and ecological responsibility. With a harmonious blend of ancient Eastern beauty practices and modern technological advancements, Florasis crafts formulas enriched with traditional Chinese medicine (TCM) floral essences. This innovative approach not only fosters wellbeing but also positions the brand at the forefront of beauty trends. The Nomadic Glam Collection's packaging, embellished with the Ulzii knot totem and complemented by artisanal leather accessories, narrates the brand's legacy and craftsmanship. As the exclusive C-beauty brand featured at @cosme Tokyo, a testament to its unique presence in one of the world's most developed beauty markets. The event at the onset of 2023 was met with enthusiasm from a discerning Japanese audience. This ongoing engagement with @cosme Tokyo cements Florasis' commitment to the Japanese market, showcasing the brand's innovative beauty narratives in a nation celebrated for its beauty industry excellence. Building on the overwhelming response to the Blooming Rouge Love Lock Lipstick's debut in Japan in 2021. An annual investment exceeding $27 million into research and development reflects Florasis' in-depth understanding of consumer preferences, as evidenced by the warm reception of products like the Floral Engraving Phoenix Makeup Palette and the Flawless Jade Breathable Setting Powder. As part of a strategic global expansion, the brand is on course to establish 25 stores in Japan, contributing to the overarching goal of establishing a robust international presence. Florasis cordially invites all to join the celebration of beauty and heritage at the @cosme Tokyo store. For further details on the pop-up event and to explore the Nomadic Glam Collection, please visit the official website or follow @florasis.official on social media. About Florasis:  Founded in 2017 by the scenic West Lake in China, Florasis stands at the crossroads of ancient heritage and modern elegance, transforming time-honored beauty insights into present-day treasures. The brand is a testament to the synergy between artistry, nature, and scientific innovation, integrating time-tested floral and herbal extracts into contemporary formulations. Florasis offers a diverse product range, including face primers, foundations, blushes, highlighters, eye shadow palettes, skincare, and lipsticks. Products are available for purchase on Florasis.com and Amazon.

文章來源 : PR Newswire 美通社 發表時間 : 瀏覽次數 : 384 加入收藏 :
首 頁 我的收藏 搜 尋 新聞發佈